In a significant pre-IPO move, Gujarat-based healthcare provider Gujarat Kidney and Super Speciality has successfully mobilised substantial funds from institutional investors. The company announced on Friday that it secured over ₹100 crore from anchor investors ahead of its forthcoming initial public offering (IPO).
Anchor Investment Details and Marquee Participants
According to an official filing with the stock exchanges, the company allocated a total of 87,73,120 equity shares to anchor investors at a price of ₹114 per share. This anchor book round saw participation from several prominent domestic and international funds, highlighting strong institutional confidence in the healthcare firm's prospects.
The list of marquee anchor investors includes Venus Investments VCC – Venus Stellar Fund, Khandelwal Finance Private Limited, Craft Emerging Market Fund PCC Citadel Capital Fund, and Nexus Global Opportunities Fund. Other key participants were Arnesta Global Opportunities Fund PCC – Arnesta Global Fund 1, Zeta Global Funds – Zeta Series C Fund PC, Innovative Vision Fund, Religo Commodities Ventures Trust, and Sunrise Investment Trust.
IPO Structure and Key Dates
The public offering of Gujarat Kidney and Super Speciality is a fresh issue of up to 2.20 crore equity shares. At the upper price band of ₹114 per share, the total issue size aggregates to ₹250.8 crore.
The subscription window for the IPO is set to open on Monday, December 22, 2025, and will close on Wednesday, December 24, 2025. Investors can bid for a minimum lot of 128 equity shares and in multiples thereafter.
The issue follows the book-building process, with the net offer allocated to different investor categories. Qualified institutional buyers (QIBs) have been reserved up to 75% of the net offer. The remaining portion is split between non-institutional investors (up to 15%) and retail individual investors (up to 10%).
Nirbhay Capital Services Private Limited is the book-running lead manager for this IPO, while MUFG Intime India Limited is serving as the registrar to the issue.
Company Profile and Grey Market Premium (GMP)
Gujarat Kidney and Super Speciality operates as a regional healthcare provider with a network of mid-sized multi-speciality hospitals located in central Gujarat. The company's business model focuses on delivering integrated healthcare services, with a core strength in secondary and tertiary care.
Its secondary services encompass various surgical procedures, while tertiary services involve super-speciality surgical treatments. The hospitals also offer comprehensive diagnostic facilities, managed both in-house and through partner networks, alongside in-house pharmacies for patient convenience.
Reflecting the market's anticipation, the IPO shares are currently commanding a premium in the grey market. As per data from Investorgain, the Grey Market Premium (GMP) for Gujarat Kidney and Super Speciality IPO is ₹7. This indicates an estimated listing price of around ₹121 per share, which would be approximately 6.14% higher than the IPO price of ₹114.
Disclaimer: This news article is for informational purposes only. The views and recommendations mentioned are those of individual analysts or broking firms. Readers are advised to consult with certified investment experts before making any financial decisions.
